104261-69-0

Basic information

• Product Name: [1-hydroxy-3-(pyridin-3-yl)propane-1,1-diyl]bis(phosphonic acid)
• CAS NO: 104261-69-0
• Molecular Formula: C₈H₁₃NO₇P₂
• Molecular Weight: 297.1388
• Mol File: 104261-69-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 691.5°C at 760 mmHg
• Flash Point: 372°C
• Density: 1.77g/cm³
• Vapor Pressure: 4.47E-20mmHg at 25°C
• Refractive Index: 1.632
• CAS DataBase Reference: [1-hydroxy-3-(pyridin-3-yl)propane-1,1-diyl]bis(phosphonic acid)(CAS DataBase Reference)
• NIST Chemistry Reference: [1-hydroxy-3-(pyridin-3-yl)propane-1,1-diyl]bis(phosphonic acid)(104261-69-0)
• EPA Substance Registry System: [1-hydroxy-3-(pyridin-3-yl)propane-1,1-diyl]bis(phosphonic acid)(104261-69-0)

Safety Data

• Hazardous Substances Data: 104261-69-0(Hazardous Substances Data)

Upstream product

• 3724-19-4 3-pyridine propionic acid 

Downstream Products

• 153692-15-0 3-(3-hydroxy-3,3-diphosphonopropyl)-1-methylpyridinium hydroxide 

Relevant articles and documents

Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: A potential route to chemotherapy

We have investigated the effects in vitro of a series of bisphosphonates on the proliferation of Trypanosoma cruzi, Trypanosoma brucei rhodesiense, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum. The results show that nitrogen-containing bisphosphonates of the type used in bone resorption therapy have significant activity against parasites, with the aromatic species having in some cases nanomolar or low-micromolar IC50 activity values against parasite replication (e.g. o-risedronate, I50 = 220 nM for T. brucei rhodesiense; risedronate, IC50 = 490 nM for T. gondii). In T. cruzi, the nitrogen-containing bisphosphonate risedronate is shown to inhibit sterol biosynthesis at a pre-squalene level, most likely by inhibiting farnesylpyrophosphate synthase. Bisphosphonates therefore appear to have potential in treating parasitic protozoan diseases.

Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque

The present invention relates to quaternary nitrogen-containing phosphonate compounds, and the pharmaceutically-acceptable salts and esters thereof and having the general structure: STR1 wherein R1, R2, R5 and R8 are defined in claim 1, m and n are integers from 0 to 10; m+n is from 0 to 10; Z is a saturated, unsaturated, or aromatic, monocyclic or polycyclic carbocycle or monocyclic or polycyclic heterocycle containing one or more heteroatoms selected from O, S, or N, wherein at least one heteroatom is a quaternary nitrogen atom; R is COOH; PO3 H2 ; SO3 H; or P(O)(OH)R4, wherein R4 is substituted or unsubstituted alkyl of 1-8 carbon atoms; The present invention further relates to pharmaceutical compositions containing a safe and effective amount of a compound of the present invention, and pharmaceutically-acceptable excipients. Finally, the present invention relates to methods for treating or preventing pathological conditions characterized by abnormal calcium and phosphate metabolism such as osteoporosis, rheumatoid arthritis, and osteoarthritis in humans or other mammals and to methods for treating or preventing dental calculus, plaque and gingivitis.